The global hormonal contraceptives market size was estimated to be USD 25.13 billion in 2023 and is expected to reach at USD 44.07 billion by 2034 with a CAGR of 5.24% during the forecast period 2024-2034. Rising introduction of hormonal contraceptive implants & vaginal rings, increasing awareness in emerging economies regarding hormonal contraception methods, growing investments by the major players for the R&D of novel contraceptive devices, supportive initiatives by various governments to increase access to contraceptive products, rising awareness regarding the various options available to avoid pregnancy, the key companies are collaborating with eminent personalities, surge in introduction of novel drugs, and increasing approval of innovative hormonal contraceptives are some of the key factors boosting the market growth.
Increasing approval of innovative hormonal contraceptives by regulatory authorities is predicted to boost the market growth during the forecast period. Hormonal contraceptives are a form of birth control that operates on the endocrine system. These methods involve the utilization of naturally occurring female hormones like estrogen and progesterone to inhibit ovulation and, consequently, prevent pregnancy. It's important to note that these contraceptives do not offer protection against HIV or other sexually transmitted infections. The development of innovative hormonal contraceptives is underway within the market to enhance efficacy and options in preventing unwanted pregnancies. For instance, in August 2022, The U.S. FDA has granted approval for Bayer's Mirena, a long-acting reversible intrauterine system. This contraceptive option provides the lengthiest period of prevention, with effectiveness lasting up to six to eight years.
By product, pills was the highest revenue-grossing segment in the global hormonal contraceptives market in 2023 owing to the enhanced availability of combination pills, their cost-effectiveness, and regulatory approval signalling the green light for combination pill usage, companies concentrating on launching new products and enhancing the formulation of hormonal contraceptives. For instance, in July 2022, Perrigo Company Plc has officially filed an application with the United States Food and Drug Administration, seeking approval for what could potentially be among the initial over-the-counter (OTC) birth control pills in the United States. The application specifically focuses on switching Opill, a daily progestin-based birth control pill, from prescription (Rx) status to over-the-counter availability. Additionally, implants is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for contraceptive implants and rising number of product launches.
By hormones, combination hormonal contraceptives was the highest revenue-grossing segment in the global hormonal contraceptives market in 2023 owing to the reduced pregnancy risk of this contraceptive is attributed to its dual mechanism, enhancing overall efficacy. Additionally, these contraceptives are linked to a decreased likelihood of developing acne when compared to contraceptives containing only progestin. Additionally, progestin-only contraceptives is predicted to grow at fastest CAGR during the forecast period as these medications exhibit no side effects related to estrogen, such as migraines and fluid retention. This absence of estrogen-related issues, coupled with an increasing number of collaborations among market players, is noteworthy. Furthermore, both contraceptives share similar effects, eliminating the need for additional contraceptive methods when used within 5 days of menstrual bleeding. For instance, in July 2022, Organon, a worldwide women's healthcare company, has partnered with Cirqle Biomedical to engage in a research collaboration and an exclusive license agreement. This collaboration is focused on the development of a novel investigational non-hormonal, on-demand contraceptive candidate.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global hormonal contraceptives market in 2023 owing to a preference for irreversible contraception among women, an increase in the introduction of innovative intrauterine devices by companies, the establishment of multispecialty hospitals, rising investment aimed at improving hospital pharmacies, and growing demand for hormonal contraceptives due to an unmet need. For instance, in July 2022, Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA have launched NEXTSTELLIS, a revolutionary oral contraceptive in Australia. Distinguished by its composition of 14.2 mg of estetrol and 3 mg drospirenone in tablet form, this contraceptive marks one of the first oral contraceptives in the country to feature a distinctive estrogen component. Additionally, retail pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the proliferation of retail pharmacy outlets in both developed and developing economies is on the rise, accompanied by an increasing embrace of e-commerce. Additionally, there is a notable involvement of governments through active initiatives focused on women's reproductive health.
North America region is anticipated for the highest revenue share during the forecast period owing to the strategic existence of major pharmaceutical industry players, a rise in the occurrence of unintended teenage pregnancies, enhanced awareness regarding diverse hormonal contraceptive approaches, and the introduction of new contraceptive drugs. For instance, in January 2022, The National Population and Family Planning Agency introduced progestin, a secure contraceptive pill designed for nursing mothers. This initiative aims to support breast milk production and promote exclusive breastfeeding, contributing to the prevention of infant stunting. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the enhanced expansion in the pharmaceutical industry, increasing consciousness about contraception, governmental initiatives to implement measures for population control, a rise in healthcare expenditures, growing technological progress, and the escalation of awareness programs concerning birth control methods and sexually transmitted diseases (STDs). For instance, in October 2023, The Karnataka state government has introduced two novel birth control methods under the National Family Planning Programme. The initial method involves a single-rod subdermal implant accessible in Bengaluru and Bidar districts, while the second method encompasses a subcutaneous injectable contraceptive to be launched in Yadgir and Mysuru districts. These contraceptives are designed to mitigate maternal and infant health concerns and are suitable for use by breastfeeding or unmarried women.
Increasing approval of innovative hormonal contraceptives by regulatory authorities is predicted to boost the market growth during the forecast period. Hormonal contraceptives are a form of birth control that operates on the endocrine system. These methods involve the utilization of naturally occurring female hormones like estrogen and progesterone to inhibit ovulation and, consequently, prevent pregnancy. It's important to note that these contraceptives do not offer protection against HIV or other sexually transmitted infections. The development of innovative hormonal contraceptives is underway within the market to enhance efficacy and options in preventing unwanted pregnancies. For instance, in August 2022, The U.S. FDA has granted approval for Bayer's Mirena, a long-acting reversible intrauterine system. This contraceptive option provides the lengthiest period of prevention, with effectiveness lasting up to six to eight years.
By product, pills was the highest revenue-grossing segment in the global hormonal contraceptives market in 2023 owing to the enhanced availability of combination pills, their cost-effectiveness, and regulatory approval signalling the green light for combination pill usage, companies concentrating on launching new products and enhancing the formulation of hormonal contraceptives. For instance, in July 2022, Perrigo Company Plc has officially filed an application with the United States Food and Drug Administration, seeking approval for what could potentially be among the initial over-the-counter (OTC) birth control pills in the United States. The application specifically focuses on switching Opill, a daily progestin-based birth control pill, from prescription (Rx) status to over-the-counter availability. Additionally, implants is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for contraceptive implants and rising number of product launches.
By hormones, combination hormonal contraceptives was the highest revenue-grossing segment in the global hormonal contraceptives market in 2023 owing to the reduced pregnancy risk of this contraceptive is attributed to its dual mechanism, enhancing overall efficacy. Additionally, these contraceptives are linked to a decreased likelihood of developing acne when compared to contraceptives containing only progestin. Additionally, progestin-only contraceptives is predicted to grow at fastest CAGR during the forecast period as these medications exhibit no side effects related to estrogen, such as migraines and fluid retention. This absence of estrogen-related issues, coupled with an increasing number of collaborations among market players, is noteworthy. Furthermore, both contraceptives share similar effects, eliminating the need for additional contraceptive methods when used within 5 days of menstrual bleeding. For instance, in July 2022, Organon, a worldwide women's healthcare company, has partnered with Cirqle Biomedical to engage in a research collaboration and an exclusive license agreement. This collaboration is focused on the development of a novel investigational non-hormonal, on-demand contraceptive candidate.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global hormonal contraceptives market in 2023 owing to a preference for irreversible contraception among women, an increase in the introduction of innovative intrauterine devices by companies, the establishment of multispecialty hospitals, rising investment aimed at improving hospital pharmacies, and growing demand for hormonal contraceptives due to an unmet need. For instance, in July 2022, Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA have launched NEXTSTELLIS, a revolutionary oral contraceptive in Australia. Distinguished by its composition of 14.2 mg of estetrol and 3 mg drospirenone in tablet form, this contraceptive marks one of the first oral contraceptives in the country to feature a distinctive estrogen component. Additionally, retail pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the proliferation of retail pharmacy outlets in both developed and developing economies is on the rise, accompanied by an increasing embrace of e-commerce. Additionally, there is a notable involvement of governments through active initiatives focused on women's reproductive health.
North America region is anticipated for the highest revenue share during the forecast period owing to the strategic existence of major pharmaceutical industry players, a rise in the occurrence of unintended teenage pregnancies, enhanced awareness regarding diverse hormonal contraceptive approaches, and the introduction of new contraceptive drugs. For instance, in January 2022, The National Population and Family Planning Agency introduced progestin, a secure contraceptive pill designed for nursing mothers. This initiative aims to support breast milk production and promote exclusive breastfeeding, contributing to the prevention of infant stunting. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the enhanced expansion in the pharmaceutical industry, increasing consciousness about contraception, governmental initiatives to implement measures for population control, a rise in healthcare expenditures, growing technological progress, and the escalation of awareness programs concerning birth control methods and sexually transmitted diseases (STDs). For instance, in October 2023, The Karnataka state government has introduced two novel birth control methods under the National Family Planning Programme. The initial method involves a single-rod subdermal implant accessible in Bengaluru and Bidar districts, while the second method encompasses a subcutaneous injectable contraceptive to be launched in Yadgir and Mysuru districts. These contraceptives are designed to mitigate maternal and infant health concerns and are suitable for use by breastfeeding or unmarried women.
Segmentation: Hormonal Contraceptives Market Report 2023 - 2034
Hormonal Contraceptives Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Intrauterine Devices
- Pills
- Implants
- Injectable
- Vaginal Rings
- Others
Hormonal Contraceptives Market Analysis & Forecast by Hormones 2023 - 2034 (Revenue USD Bn)
- Progestin-Only
- Combination Hormonal Contraceptives
Hormonal Contraceptives Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Hormonal Contraceptives Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Hormonal Contraceptives Market: Product Estimates & Trend Analysis
8. Hormonal Contraceptives Market: Hormones Estimates & Trend Analysis
9. Hormonal Contraceptives Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Hormonal Contraceptives Market
12. Europe Global Hormonal Contraceptives Market
13. Asia Pacific Global Hormonal Contraceptives Market
14. Latin America Global Hormonal Contraceptives Market
15. MEA Global Hormonal Contraceptives Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Bayer AG
- Merck & Co. Inc.
- Teva Pharmaceutical Industries
- Afaxys Inc.
- Janssen Pharmaceuticals Inc.
- Allergan
- Pregna International Ltd.
- Novartis AG
- Pfizer Inc.
- Organon Group of Companies
- Mylan N.V.
- Lupin Pharmaceuticals Inc.
- Agile Therapeutics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 25.13 Billion |
| Forecasted Market Value ( USD | $ 44.07 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
